Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 11/20 | 0.60 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.43 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.43 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669288 | 0.89 | GCK (0.53) | GCKFFAR2KCNMA1KCNH2HSPA5 | |
| SCHEMBL2513208 | 0.78 | HSPA5 (0.46) | GCKKMT2AKCNH2HSPA5HSPA1A | |
| SCHEMBL7514601 | 0.77 | GCK (1.00) | GCKKCNMA1KMT2APOLB | |
| SCHEMBL2646757 | 0.74 | FFAR2 (0.91) | GCKFFAR2KMT2AKCNH2EPHX2 | |
| SCHEMBL12228085 | 0.73 | HSPA5 (0.46) | GCKHSPA5HSPA1AHSPA9HSPA2 | |
| SCHEMBL2672708 | 0.73 | EPHX2 (0.60) | GCKFFAR2KMT2AKCNH2POLB | |
| SCHEMBL1316330 | 0.73 | EPHX2 (0.60) | GCKFFAR2KMT2AKCNH2POLB | |
| SCHEMBL2656985 | 0.72 | FFAR2 (0.70) | GCKFFAR2KMT2AKCNH2EPHX2 | |
| SCHEMBL2659403 | 0.72 | CTSK (0.55) | GCKFFAR2KCNH2POLBEPHX2 | |
| SCHEMBL12228038 | 0.72 | CTSK (0.55) | GCKFFAR2KCNH2POLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885FFAR2 2244/4885KCNMA1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.